Parathyroidectomy Improves the Consumption of Erythropoiesis-Stimulating Agents in Hemodialysis Patients

Chia Nan University of Pharmacy & Science Institutional Repository > 行政單位 > 123 > Item 310902800/34600

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34600

標題:	Parathyroidectomy Improves the Consumption of Erythropoiesis-Stimulating Agents in Hemodialysis Patients
作者:	Lee, Yu-Ting Tu, Chi-Wen Kam, Kam-Hong Ma, Tsung-Liang Kuo, Chin-Ho Lee, Ming-Yang Hsiao, Chih-Yen Chan, Michael W. Y. Hung, Peir-Haur
貢獻者:	Chia-Yi Christian Hospital National Chung Cheng University National Chung Cheng University National Chung Cheng University Chia-Yi Christian Hospital Chia-Yi Christian Hospital Chia-Yi Christian Hospital Chia Nan University of Pharmacy & Science Chia Nan University of Pharmacy & Science
關鍵字:	renal-disease patients bone-marrow fibrosis anemia hormone therapy
日期:	2022
上傳時間:	2023-12-11 14:00:00 (UTC+8)
出版者:	MDPI
摘要:	Secondary hyperparathyroidism (SHPT) is common in end-stage renal disease (ESRD) patients, and it can suppress erythropoiesis. We aimed to investigate the relationship between the consumption of erythropoiesis-stimulating agents (ESAs) and parathyroidectomy (PTX) in ESRD patients with SHPT and to determine the predictors for anemia improvement. The current standard of chronic kidney disease anemia therapy relies on the prescription of iron supplementation, and ESA. We retrospectively analyzed 81 ESRD patients with PTX at Ditmanson Medical Foundation Chiayi Christian Hospital from July 2004 to Dec 2018. The requirement of ESA therapy markedly declined from a dose of 41.6 (interquartile range [IQR], 0-91.2) to 10.3 (IQR, 0-59.5, p = 0.001) unit/kg/week. In addition, 63.7% of patients required iron replacement therapy preoperatively and the proportion reduced to 52.5% after PTX (p < 0.001). The hemoglobin (Hb) level showed an insignificant change from a median value of 10.7 g/dL (9.5-11.6 g/dL) before PTX to 10.5 g/dL (9.6-11.2 g/dL) at 6 months after PTX. A preoperative Hb level <= 10 mg/dL (odds ratio [OR], 20.1; 95% confidence interval [CI], 4.71-125, p < 0.001) and transferrin saturation (TSAT) < 25% (OR, 12.8; 95% CI, 2.51-129, p < 0.001) were predictors for anemia improvement. Our study demonstrated that PTX markedly decreased the requirement of ESA. Patients with a low preoperative Hb level or low TSAT showed an increase in the Hb level after PTX. PTX may be considered not only for SHPT with refractory anemia but also for high ESA-dependent patients.
關聯:	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, v.23, n.CB2, pp.CC2, pp.-,
显示于类别:	[行政單位] 123

文件中的档案:

档案	描述	大小	格式	浏览次数
index.html		0Kb	HTML	75	检视/开启

在CNU IR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....